The carbapenem antibiotics (imipenem, meropenem and doripenem) are considered the agents of choice for A. baumannii infections. The presence of resistance to these agents constrains therapeutic ...

Acinetobacter baumannii has emerged in the last decades as a major cause of healthcare-associated infections and nosocomial outbreaks. Multidrug-resistant (MDR) A. baumannii is a rapidly emerging ...

The drug – called zosurabalpin – has been shown to be effective against carbapenem-resistant Acinetobacter baumannii or CRAB in animal models of serious infections and has now advanced into ...

E. coli is also resistant to carbapenem. 3. Acinetobacter baumannii Back in 2012, researchers described Acinetobacter baumannii as an "emerging opportunistic bacterial pathogen" associated with ...

Osta Therapeutics, a biotechnology company developing smart drugs to fight antibiotic resistance, today announced the appointments of Dr. Gilles Courtemanche as Senior Scientific Advisor and Dr.

A lack of effective antibiotics for harmful bacteria such as Acinetobacter baumannii ... Mortality rates for pneumonia caused by carbapenem-resistant A. baumannii (CRAB)—a Gram-negative pathogen ...

including carbapenem-resistant Acinetobacter baumannii, carbapenem-resistant Pseudomonas aeruginosa, and CRE. Global phase 3 studies are ongoing in subjects with hospital- and ventilator-acquired ...

HC Wainwright reiterated their buy rating on shares of Spero Therapeutics (NASDAQ:SPRO – Free Report) in a research note issued to investors on Thursday morning,Benzinga reports. HC Wainwright ...

BV100 is a new formulation of rifabutin suitable for intravenous administration, which BioVersys claims offers a new ...

Testing new antibiotics in India, South Africa, or Brazil, where they are needed most, makes scientific sense. But it’s not without challenges. If the drugs lack global viability, they are less likely ...

E. coli is also resistant to carbapenem. Back in 2012, researchers described Acinetobacter baumannii as an "emerging opportunistic bacterial pathogen" associated with hospital-acquired infections ...

Among the most important AMR targets are carbapenem-resistant bacteria. In Latin America, it appears that bacteria resistant to carbapenem antibiotics have different resistance mechanisms than ...